Researchers at Mayo Clinic have validated preclinical findings for ADI-100, an innovative autoimmune therapy candidate developed by Aditxt's subsidiary Adimune Inc. The study confirmed the treatment's ability to induce immune tolerance to glutamic acid decarboxylase (GAD), a critical protein involved in several autoimmune disorders.
The research revealed that ADI-100 does not enhance harmful immune activity. Instead, it promotes antigen-specific suppression through tolerogenic dendritic cells, representing a potential breakthrough in managing autoimmune conditions. This mechanism could provide new therapeutic approaches for patients with type 1 diabetes and stiff person syndrome.
Aditxt has completed Good Manufacturing Practice (GMP) manufacturing for ADI-100 and is currently conducting stability testing. The company plans to file regulatory submissions in the United States and Germany during the second half of 2025, paving the way for upcoming clinical trials.
The study's results represent a significant step forward in developing targeted immunotherapies that could potentially modify disease progression for patients with challenging autoimmune disorders. By focusing on inducing immune tolerance rather than suppressing the entire immune system, ADI-100 offers a more precise and potentially less disruptive treatment approach.
